Home Healthcare Pharmaceuticals Dementia Drugs Market

Dementia Drugs Market Size, Share & Trends Analysis Report By Indications (Lewy Body Dementia, Parkinsons Disease Dementia, Alzheimers Disease, Vascular Dementia, Other Indications), By Drug Class (MAO-B Inhibitors, Glutamate Inhibitors, Cholinesterase Inhibitors) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: May 25, 2026 | Author: Mitiksha Koul | Format: | Report Code: SR3267DR | Pages: 156
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Dementia Drugs Market, By Indications 2022-2034 (USD MILLION/ Units)
    1. Lewy Body Dementia
    2. Parkinsons Disease Dementia
    3. Alzheimers Disease
    4. Vascular Dementia
    5. Other Indications
  2. Dementia Drugs Market, By Drug Class 2022-2034 (USD MILLION/ Units)
    1. MAO-B Inhibitors
    2. Glutamate Inhibitors
    3. Cholinesterase Inhibitors
  3. Regional Dementia Drugs Market
    1. North America
      1. North America Dementia Drugs Market By Indications 2022-2034 (USD MILLION/ Units)
        1. Lewy Body Dementia
        2. Parkinsons Disease Dementia
        3. Alzheimers Disease
        4. Vascular Dementia
        5. Other Indications
      2. North America Dementia Drugs Market By Drug Class 2022-2034 (USD MILLION/ Units)
        1. MAO-B Inhibitors
        2. Glutamate Inhibitors
        3. Cholinesterase Inhibitors
      3. U.S.
        1. Lewy Body Dementia
        2. Parkinsons Disease Dementia
        3. Alzheimers Disease
        4. Vascular Dementia
        5. Other Indications
        6. MAO-B Inhibitors
        7. Glutamate Inhibitors
        8. Cholinesterase Inhibitors
      4. Canada
        1. Lewy Body Dementia
        2. Parkinsons Disease Dementia
        3. Alzheimers Disease
        4. Vascular Dementia
        5. Other Indications
        6. MAO-B Inhibitors
        7. Glutamate Inhibitors
        8. Cholinesterase Inhibitors
    2. Europe
      1. Europe Dementia Drugs Market By Indications 2022-2034 (USD MILLION/ Units)
        1. Lewy Body Dementia
        2. Parkinsons Disease Dementia
        3. Alzheimers Disease
        4. Vascular Dementia
        5. Other Indications
      2. Europe Dementia Drugs Market By Drug Class 2022-2034 (USD MILLION/ Units)
        1. MAO-B Inhibitors
        2. Glutamate Inhibitors
        3. Cholinesterase Inhibitors
      3. U.K.
        1. Lewy Body Dementia
        2. Parkinsons Disease Dementia
        3. Alzheimers Disease
        4. Vascular Dementia
        5. Other Indications
        6. MAO-B Inhibitors
        7. Glutamate Inhibitors
        8. Cholinesterase Inhibitors
      4. Germany
        1. Lewy Body Dementia
        2. Parkinsons Disease Dementia
        3. Alzheimers Disease
        4. Vascular Dementia
        5. Other Indications
        6. MAO-B Inhibitors
        7. Glutamate Inhibitors
        8. Cholinesterase Inhibitors
      5. France
        1. Lewy Body Dementia
        2. Parkinsons Disease Dementia
        3. Alzheimers Disease
        4. Vascular Dementia
        5. Other Indications
        6. MAO-B Inhibitors
        7. Glutamate Inhibitors
        8. Cholinesterase Inhibitors
      6. Spain
        1. Lewy Body Dementia
        2. Parkinsons Disease Dementia
        3. Alzheimers Disease
        4. Vascular Dementia
        5. Other Indications
        6. MAO-B Inhibitors
        7. Glutamate Inhibitors
        8. Cholinesterase Inhibitors
      7. Italy
        1. Lewy Body Dementia
        2. Parkinsons Disease Dementia
        3. Alzheimers Disease
        4. Vascular Dementia
        5. Other Indications
        6. MAO-B Inhibitors
        7. Glutamate Inhibitors
        8. Cholinesterase Inhibitors
      8. Russia
        1. Lewy Body Dementia
        2. Parkinsons Disease Dementia
        3. Alzheimers Disease
        4. Vascular Dementia
        5. Other Indications
        6. MAO-B Inhibitors
        7. Glutamate Inhibitors
        8. Cholinesterase Inhibitors
      9. Nordic
        1. Lewy Body Dementia
        2. Parkinsons Disease Dementia
        3. Alzheimers Disease
        4. Vascular Dementia
        5. Other Indications
        6. MAO-B Inhibitors
        7. Glutamate Inhibitors
        8. Cholinesterase Inhibitors
      10. Benelux
        1. Lewy Body Dementia
        2. Parkinsons Disease Dementia
        3. Alzheimers Disease
        4. Vascular Dementia
        5. Other Indications
        6. MAO-B Inhibitors
        7. Glutamate Inhibitors
        8. Cholinesterase Inhibitors
      11. Rest of Europe
        1. Lewy Body Dementia
        2. Parkinsons Disease Dementia
        3. Alzheimers Disease
        4. Vascular Dementia
        5. Other Indications
        6. MAO-B Inhibitors
        7. Glutamate Inhibitors
        8. Cholinesterase Inhibitors
    3. APAC
      1. APAC Dementia Drugs Market By Indications 2022-2034 (USD MILLION/ Units)
        1. Lewy Body Dementia
        2. Parkinsons Disease Dementia
        3. Alzheimers Disease
        4. Vascular Dementia
        5. Other Indications
      2. APAC Dementia Drugs Market By Drug Class 2022-2034 (USD MILLION/ Units)
        1. MAO-B Inhibitors
        2. Glutamate Inhibitors
        3. Cholinesterase Inhibitors
      3. China
        1. Lewy Body Dementia
        2. Parkinsons Disease Dementia
        3. Alzheimers Disease
        4. Vascular Dementia
        5. Other Indications
        6. MAO-B Inhibitors
        7. Glutamate Inhibitors
        8. Cholinesterase Inhibitors
      4. Korea
        1. Lewy Body Dementia
        2. Parkinsons Disease Dementia
        3. Alzheimers Disease
        4. Vascular Dementia
        5. Other Indications
        6. MAO-B Inhibitors
        7. Glutamate Inhibitors
        8. Cholinesterase Inhibitors
      5. Japan
        1. Lewy Body Dementia
        2. Parkinsons Disease Dementia
        3. Alzheimers Disease
        4. Vascular Dementia
        5. Other Indications
        6. MAO-B Inhibitors
        7. Glutamate Inhibitors
        8. Cholinesterase Inhibitors
      6. India
        1. Lewy Body Dementia
        2. Parkinsons Disease Dementia
        3. Alzheimers Disease
        4. Vascular Dementia
        5. Other Indications
        6. MAO-B Inhibitors
        7. Glutamate Inhibitors
        8. Cholinesterase Inhibitors
      7. Australia
        1. Lewy Body Dementia
        2. Parkinsons Disease Dementia
        3. Alzheimers Disease
        4. Vascular Dementia
        5. Other Indications
        6. MAO-B Inhibitors
        7. Glutamate Inhibitors
        8. Cholinesterase Inhibitors
      8. Taiwan
        1. Lewy Body Dementia
        2. Parkinsons Disease Dementia
        3. Alzheimers Disease
        4. Vascular Dementia
        5. Other Indications
        6. MAO-B Inhibitors
        7. Glutamate Inhibitors
        8. Cholinesterase Inhibitors
      9. South East Asia
        1. Lewy Body Dementia
        2. Parkinsons Disease Dementia
        3. Alzheimers Disease
        4. Vascular Dementia
        5. Other Indications
        6. MAO-B Inhibitors
        7. Glutamate Inhibitors
        8. Cholinesterase Inhibitors
      10. Rest of Asia-Pacific
        1. Lewy Body Dementia
        2. Parkinsons Disease Dementia
        3. Alzheimers Disease
        4. Vascular Dementia
        5. Other Indications
        6. MAO-B Inhibitors
        7. Glutamate Inhibitors
        8. Cholinesterase Inhibitors
    4. Middle East and Africa
      1. Middle East and Africa Dementia Drugs Market By Indications 2022-2034 (USD MILLION/ Units)
        1. Lewy Body Dementia
        2. Parkinsons Disease Dementia
        3. Alzheimers Disease
        4. Vascular Dementia
        5. Other Indications
      2. Middle East and Africa Dementia Drugs Market By Drug Class 2022-2034 (USD MILLION/ Units)
        1. MAO-B Inhibitors
        2. Glutamate Inhibitors
        3. Cholinesterase Inhibitors
      3. UAE
        1. Lewy Body Dementia
        2. Parkinsons Disease Dementia
        3. Alzheimers Disease
        4. Vascular Dementia
        5. Other Indications
        6. MAO-B Inhibitors
        7. Glutamate Inhibitors
        8. Cholinesterase Inhibitors
      4. Turkey
        1. Lewy Body Dementia
        2. Parkinsons Disease Dementia
        3. Alzheimers Disease
        4. Vascular Dementia
        5. Other Indications
        6. MAO-B Inhibitors
        7. Glutamate Inhibitors
        8. Cholinesterase Inhibitors
      5. Saudi Arabia
        1. Lewy Body Dementia
        2. Parkinsons Disease Dementia
        3. Alzheimers Disease
        4. Vascular Dementia
        5. Other Indications
        6. MAO-B Inhibitors
        7. Glutamate Inhibitors
        8. Cholinesterase Inhibitors
      6. South Africa
        1. Lewy Body Dementia
        2. Parkinsons Disease Dementia
        3. Alzheimers Disease
        4. Vascular Dementia
        5. Other Indications
        6. MAO-B Inhibitors
        7. Glutamate Inhibitors
        8. Cholinesterase Inhibitors
      7. Egypt
        1. Lewy Body Dementia
        2. Parkinsons Disease Dementia
        3. Alzheimers Disease
        4. Vascular Dementia
        5. Other Indications
        6. MAO-B Inhibitors
        7. Glutamate Inhibitors
        8. Cholinesterase Inhibitors
      8. Nigeria
        1. Lewy Body Dementia
        2. Parkinsons Disease Dementia
        3. Alzheimers Disease
        4. Vascular Dementia
        5. Other Indications
        6. MAO-B Inhibitors
        7. Glutamate Inhibitors
        8. Cholinesterase Inhibitors
      9. Rest of MEA
        1. Lewy Body Dementia
        2. Parkinsons Disease Dementia
        3. Alzheimers Disease
        4. Vascular Dementia
        5. Other Indications
        6. MAO-B Inhibitors
        7. Glutamate Inhibitors
        8. Cholinesterase Inhibitors
    5. LATAM
      1. LATAM Dementia Drugs Market By Indications 2022-2034 (USD MILLION/ Units)
        1. Lewy Body Dementia
        2. Parkinsons Disease Dementia
        3. Alzheimers Disease
        4. Vascular Dementia
        5. Other Indications
      2. LATAM Dementia Drugs Market By Drug Class 2022-2034 (USD MILLION/ Units)
        1. MAO-B Inhibitors
        2. Glutamate Inhibitors
        3. Cholinesterase Inhibitors
      3. Brazil
        1. Lewy Body Dementia
        2. Parkinsons Disease Dementia
        3. Alzheimers Disease
        4. Vascular Dementia
        5. Other Indications
        6. MAO-B Inhibitors
        7. Glutamate Inhibitors
        8. Cholinesterase Inhibitors
      4. Mexico
        1. Lewy Body Dementia
        2. Parkinsons Disease Dementia
        3. Alzheimers Disease
        4. Vascular Dementia
        5. Other Indications
        6. MAO-B Inhibitors
        7. Glutamate Inhibitors
        8. Cholinesterase Inhibitors
      5. Argentina
        1. Lewy Body Dementia
        2. Parkinsons Disease Dementia
        3. Alzheimers Disease
        4. Vascular Dementia
        5. Other Indications
        6. MAO-B Inhibitors
        7. Glutamate Inhibitors
        8. Cholinesterase Inhibitors
      6. Chile
        1. Lewy Body Dementia
        2. Parkinsons Disease Dementia
        3. Alzheimers Disease
        4. Vascular Dementia
        5. Other Indications
        6. MAO-B Inhibitors
        7. Glutamate Inhibitors
        8. Cholinesterase Inhibitors
      7. Colombia
        1. Lewy Body Dementia
        2. Parkinsons Disease Dementia
        3. Alzheimers Disease
        4. Vascular Dementia
        5. Other Indications
        6. MAO-B Inhibitors
        7. Glutamate Inhibitors
        8. Cholinesterase Inhibitors
      8. Rest of LATAM
        1. Lewy Body Dementia
        2. Parkinsons Disease Dementia
        3. Alzheimers Disease
        4. Vascular Dementia
        5. Other Indications
        6. MAO-B Inhibitors
        7. Glutamate Inhibitors
        8. Cholinesterase Inhibitors
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.